Tirzepatide 3mg

Administered by subcutaneous injection once weekly into the abdomen, thigh, or upper arm. Rotate injection sites with each dose. The solution should be clear, colorless to slightly yellow; do not use if cloudy or particulate matter is visible.

Tirzepatide 3 mg may be used as an initiation dose or a prescriber-individualized maintenance dose. Dose escalation follows the standard protocol:

• Titrate in 2.5 mg increments no sooner than every 4 weeks based on tolerability and therapeutic response
• Maximum approved dose for tirzepatide is 15 mg once weekly
• Final dose schedule is determined by the prescriber

• Tirzepatide: Acts as a co-agonist at both GIP and GLP-1 receptors. GLP-1 receptor agonism increases glucose-dependent insulin release, suppresses glucagon, slows gastric emptying, and reduces central appetite signaling. GIP receptor agonism synergistically amplifies insulin secretion and may modulate adipose lipid metabolism. Together, these mechanisms produce additive reductions in blood glucose and body weight exceeding those of selective GLP-1 agonists.

Indicated for type 2 diabetes mellitus management and/or chronic weight management. The 3 mg compounded strength allows prescribers to individualize the starting dose or maintenance dose for patients who require slower titration or who respond well at sub-commercial doses. Monitoring is identical to other tirzepatide preparations.

Monitoring parameters:

• HbA1c at 3-month intervals until therapeutic target is achieved
• Body weight and BMI at each visit
• Renal function if significant GI adverse effects develop
• Amylase/lipase if pancreatitis symptoms arise
• Thyroid evaluation if a nodule is detected clinically

Contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
• Hypersensitivity to tirzepatide or any excipient

Warnings & Precautions:

• Thyroid C-cell tumors (rodent carcinogenicity signal)
• Pancreatitis risk—discontinue if suspected
• Hypoglycemia when combined with insulin or sulfonylureas
• GI adverse effects: nausea, vomiting, diarrhea, constipation
• Acute kidney injury from dehydration
• Retinopathy worsening with rapid glycemic improvement

Drug Interactions:

• Insulin and secretagogues: increased hypoglycemia risk
• Oral drugs: delayed gastric emptying may alter absorption

Common Side Effects: Nausea, vomiting, diarrhea, constipation, decreased appetite, and injection site reactions.

Refrigerate at 2–8°C; protect from light; do not freeze. Use within the beyond-use date established by Genesis Compounding. Discard unused solution after BUD.

Why is 3 mg used instead of the commercial 2.5 mg or 5 mg dose?

Compounding allows prescribers to tailor the dose for individual patients. Some patients benefit from a 3 mg intermediate dose during titration or maintenance that is not available commercially.

How is this injected?

Subcutaneous injection once weekly. Rotate among the abdomen, thigh, or upper arm with each dose.

Is this FDA-approved?

Tirzepatide is FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (weight management) in commercial strengths. This 3 mg compounded preparation is a 503A patient-specific product by Genesis Compounding and is not FDA-approved as a compounded product.

What are the main side effects?

Nausea, vomiting, diarrhea, and decreased appetite are most common, especially at initiation. These typically improve over several weeks as the body adjusts.

What if I experience severe nausea?

Contact your prescriber. Dose escalation may be slowed, or a B6 supplement may be added. Staying hydrated and eating smaller, lower-fat meals can also help reduce GI symptoms.